Reports
News
Opinions
Statements
Relations
business Feb 24, 2026, 2:47 PM
Novo Nordisk cuts U.S. prices of diabetes and weight-loss drugs by half - Novo Nordisk will reduce list prices of Ozempic and Wegovy by up to 50% starting January 1, 2027.
- The price reductions will align with new pricing regulations for federal Medicare health plans.
- This decision demonstrates the company’s commitment to enhancing drug affordability in a competitive healthcare market.
100
business Feb 23, 2026, 6:31 AM
Novo Nordisk stock crashes after disappointing obesity trial results - Novo Nordisk stock dropped to a 52-week low after disappointing trial results.
- The REDEFINE 4 phase 3 trial failed to demonstrate non-inferiority of CagriSema in weight loss compared to tirzepatide.
- Management remains optimistic about future trials and the drug's potential despite the setback.
100
business Feb 12, 2026, 5:09 PM
Novo Nordisk to manufacture Wegovy in Ireland - Novo Nordisk is expanding its Irish production facility to manufacture Wegovy.
- The Athlone site will focus on producing the drug for non-US markets.
- This investment reflects the company's commitment to growth despite earlier job cuts.
100
business Feb 10, 2026, 12:53 PM
Novo Nordisk sues Hims & Hers over weight-loss drug patent infringement - Novo Nordisk filed a lawsuit against Hims & Hers for infringing on patents and health concerns related to their weight-loss drugs.
- Hims & Hers announced their intent to stop selling the disputed weight-loss pill but faced a significant drop in share price.
- Novo Nordisk aims to protect public health and its proprietary innovations through this legal action.
100
business Feb 4, 2026, 9:24 PM
Pfizer's weight loss drug shows promising trial results - Pfizer's experimental weight loss drug, PF-08653944, showed solid results in a mid-stage clinical trial with no observed plateau in weight loss by week 28.
- The drug's side effects were predominantly mild or moderate, with a few patients discontinuing treatment due to adverse effects.
- These findings position Pfizer to compete in the weight loss drug market against other companies like Amgen and Eli Lilly.
100
business Feb 4, 2026, 6:18 PM
Novo Nordisk sees surge in Wegovy pill demand after U.S. launch - The Wegovy pill was launched in the U.S. in early January 2026, quickly achieving high prescription demand.
- About 50,000 prescriptions were filled weekly within three weeks of launch, with over 170,000 total users reported.
- The early success of Wegovy signals increased availability of weight loss solutions and validates the growing trend towards preventive health.
200
science Dec 22, 2025, 7:42 PM
FDA approves Wegovy pill for effective weight loss treatment - The FDA approved the first oral version of Wegovy, a GLP-1 drug for weight loss.
- In clinical trials, participants experienced significant weight loss, averaging 16.6% body weight reduction.
- The approval of the Wegovy pill provides a new option for patients seeking effective weight management solutions.
400
business Dec 1, 2025, 2:43 PM
Eli Lilly lowers weight loss drug prices to expand access - Eli Lilly announced price cuts for Zepbound to improve patient access.
- The updated pricing includes a reduction to $299 for self-pay patients and lower prices for other dosages.
- The move highlights the competitive nature of the weight loss drug market and aims to eliminate barriers for patients.
100
science Nov 24, 2025, 1:00 AM
Novo Nordisk faces major setback after Alzheimer's trial failure - Novo Nordisk's Rybelsus failed to show efficacy in slowing cognitive decline in Alzheimer's patients during late-stage trials.
- The trial results involved 3,808 patients aged 55 to 85 and aimed for a 20% reduction in cognitive decline.
- The failure highlights the challenges facing Novo Nordisk as it encounters stiff competition in the Alzheimer's medication market.
600
society Nov 17, 2025, 2:32 PM
Novo Nordisk slashes Wegovy prices but patients still struggle with costs - Novo Nordisk has introduced a new pricing strategy for its obesity treatment Wegovy.
- Health professionals warn that ongoing affordability issues persist, especially for uninsured patients.
- The reduced prices are a step toward making weight-loss medications more accessible, but many patients still struggle financially.
200
2026 All rights reserved
2026 All rights reserved